Intuitive Surgical, Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +35

ISRG Stock: The Best House On The Block Costs The Most - Trefis

AI-generated analysis

📈 ISRG trades at a premium 42.5x earnings multiple compared to peer Medtronic's 24.2x despite recent stock underperformance.

💰 The company achieved a leading 31% operating margin, significantly outperforming the industry average and rival Medtronic's 18.8%.

🚀 Revenue grew 21% over the last twelve months, demonstrating superior execution against diversified competitors like Medtronic.

🔧 A healthy upgrade cycle is underway with 468 da Vinci systems placed in Q2, including 246 units of the new da Vinci 5 model.

🌍 International growth remains robust with procedure volume expanding 20% outside the U.S. to offset domestic market saturation.

⚠️ U.S. procedure growth has moderated due to changes in patient insurance coverage affecting deferrable surgical procedures.

🎯 Management reaffirmed a full-year guidance range for worldwide da Vinci procedure growth between 13.5% and 15.5%.

📉 The stock delivered a -21% return over the last twelve months, badly trailing the S&P 500's +19.2% gain.

Bullish Signals
  • ISRG commands the highest operating margin in its peer group at 31%, significantly outperforming rivals like Medtronic.
  • Revenue grew 21% over the last twelve months, demonstrating superior operational execution compared to diversified competitors.
  • The company is executing a powerful upgrade cycle with strong capital equipment sales, placing 468 da Vinci systems in Q2 alone.
  • International expansion provides a crucial growth offset with procedure volume growing 20% outside the U.S. market.
Risk Factors
  • The stock has delivered a -21% return over the last twelve months, significantly underperforming the S&P 500's +19.2% gain.
  • Growth in the U.S. market is moderating due to changes in patient insurance coverage affecting deferrable procedures.
Full Analysis
Intuitive Surgical (ISRG) remains the undisputed leader in robotic-assisted surgery, trading at a premium valuation of 42.5 times earnings compared to peers like Medtronic at 24.2x. Despite commanding the highest operating margin in its peer group at 31% and delivering robust revenue growth of 21% over the last twelve months, the stock has underperformed significantly with a -21% return over the past year, trailing the S&P 500's gains. The company's high valuation is driven by a strong upgrade cycle for its da Vinci 5 system, evidenced by placing 468 systems in the second quarter, with nearly half being the newer model. International expansion continues to provide crucial growth support, with procedure volume increasing 20% outside the U.S., offsetting signs of maturation in the domestic market where patient insurance changes are affecting deferrable procedures. Investors are closely watching whether ISRG can meet its full-year guidance for worldwide da Vinci procedure growth between 13.5% and 15.5%. Management has affirmed this target, suggesting that if achieved, it would validate the bull case that the U.S. slowdown is manageable. The core metric driving recurring revenue remains the number of procedures performed, making adherence to these targets critical for sustaining its premium market capitalization.